Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 523Leukemia, Myeloid, Acute 499Neoplasms 381Carcinoma, Non-Small-Cell Lung 381Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 319Multiple Myeloma 312Glioblastoma 311Melanoma 310Prostatic Neoplasms 293Leukemia 289Neoplasm Metastasis 284Brain Neoplasms 277Lymphoma 271Lung Neoplasms 270Recurrence 267Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Glioma 209Myelodysplastic Syndromes 208Lymphoma, Large B-Cell, Diffuse 186Carcinoma, Hepatocellular 173Lymphoma, Follicular 167Head and Neck Neoplasms 162Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Interventions

Ranibizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Conjunctival Neoplasms × Clear all
NCT00456495 2017-07-21

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

The New York Eye Cancer Center

Phase 1 Completed
5 enrolled 6 charts

Conjunctival Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡